Status:Stopped Early
Principal Investigator(s):Lut Van Damme, MD, MS, PhD; Amy Corneli, PhD, MPH
Objective:Investigate the safety and effectiveness of once-daily oral TDF/FTC (Truvada) in preventing HIV among women at risk of becoming infected through sexual intercourse.This study was stopped early due to futility (poor adherence)Last updated August 10, 2022
Start Date
End Date
May 31, 2009
January 31, 2013
Age range: 18 Years ↔ 35 Years
Population:Cisgender Women